IE 11 is a very old Browser and it`s not supported on this site
Financial Report

Consolidated balance sheet

(in CHF 1 000)

 

 

Notes

 

31.03.2021

 

31.12.2020

Current assets

 

 

 

 

 

 

Cash and cash equivalents

 

 

 

3 914

 

6 816

Receivables from brokers

 

 

 

 

1 521

Securities

 

4

 

4 278 768

 

3 954 659

Other assets

 

 

 

235

 

139

 

 

 

 

4 282 917

 

3 963 135

Total assets

 

 

 

4 282 917

 

3 963 135

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Short-term borrowings from banks

 

5

 

350 000

 

63 000

Payables to brokers

 

 

 

8 455

 

6 576

Other short-term liabilities

 

 

 

5 683

 

5 709

Tax liabilities

 

 

 

326

 

303

 

 

 

 

364 464

 

75 588

Total liabilities

 

 

 

364 464

 

75 588

 

 

 

 

 

 

 

Shareholders' equity

 

 

 

 

 

 

Share capital

 

6

 

11 080

 

11 080

Treasury shares

 

6

 

 

(8 241)

Retained earnings

 

 

 

3 907 373

 

3 884 708

 

 

 

 

3 918 453

 

3 887 547

Total liabilities and shareholders' equity

 

 

 

4 282 917

 

3 963 135

 

 

 

 

 

 

 

Net asset value per share in CHF

 

 

 

70.75

 

70.30

The notes are an integral part of the condensed consolidated interim financial statements.

The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on April 20, 2021.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer